MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
Rhea-AI Summary
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, will participate in the Stifel 2025 Virtual Cardiometabolic Forum. The company's leadership, including CEO Kent Hawryluk and CMO Dr. Sam Azoulay, will engage in a fireside chat on September 30, 2025, from 10:00 AM to 10:25 AM ET.
The virtual presentation will be accessible through a live webcast on the company's investor relations website, with a replay available for approximately 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MBX gained 2.46%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $19M to the company's valuation, bringing the market cap to $782M at that time.
Data tracked by StockTitan Argus on the day of publication.
CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30.
Stifel 2025 Virtual Cardiometabolic Forum
Date: Tuesday, September 30, 2025
Format: Fireside chat
Time: 10:00 a.m. – 10:25 a.m. ET
Location: Virtual
The live webcast of the presentation can be accessed in the events sections of MBX’s website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; imapextide (1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When is MBX Biosciences presenting at the Stifel 2025 Virtual Cardiometabolic Forum?
Who will be representing MBX Biosciences at the Stifel 2025 Virtual Cardiometabolic Forum?
How can investors access MBX Biosciences' presentation at the Stifel Forum?
What is MBX Biosciences' primary focus as a company?
